论文部分内容阅读
目的:观察参附注射液对NP方案治疗非小细胞肺癌患者生活质量的影响。方法:42例拟行NP方案化疗的非小细胞肺癌患者,随机分为参附先治疗组(21例)和参附后治疗组(21例)。通过随机自身前后交叉对照,观察治疗前后中医证候积分、T细胞亚群和NK细胞的变化,评估患者的生活质量的改善情况。结果:SHF+NP方案治疗后中医证候积分较其治疗前、NP方案治疗后均升高,有显著性差异(P<0.01,P<0.05),NP化疗方案治疗前后比较无显著性差异。SHF+NP方案治疗后CD4+、NK细胞较其治疗前、NP方案治疗后均升高,有显著性差异(P<0.01,P<0.05)。两方案均出现了恶心呕吐症状,与各自组前比较均有显著性差异(P<0.01)。两方案化疗后,生活质量均有不同程度的提高,其中,SHF+NP方案治疗前后改善明显,有显著性差异(P<0.01,P<0.05)。结论:在NP方案治疗非小细胞肺癌过程中联合使用参附注射液能增强肿瘤患者的细胞免疫功能,提高生活质量,对提高疗效和改善预后有一定的积极意义。
Objective: To observe the effect of Shenfu injection on the quality of life of patients with non-small cell lung cancer treated with NP regimen. Methods: Forty-two non-small cell lung cancer patients scheduled for NP regimen were randomly divided into treatment group (21 cases) and treatment group (21 cases). Before and after the random cross-control before and after treatment to observe the TCM Syndrome points, T cell subsets and NK cell changes, to assess the quality of life of patients improved. Results: The TCM syndrome scores of SHF + NP regimen were significantly higher than those before treatment and NP regimen after treatment (P <0.01, P <0.05). There was no significant difference between the two groups before and after treatment. After treatment with SHF + NP, CD4 + and NK cells were significantly higher than those before treatment and NP treatment (P <0.01, P <0.05). Nausea and vomiting were found in both regimens, with significant differences (P <0.01). The quality of life of the two regimens after chemotherapy were improved to varying degrees, of which, SHF + NP regimen improved significantly before and after treatment, there was a significant difference (P <0.01, P <0.05). Conclusion: The combination of Shenfu injection with NP regimen in the treatment of non-small cell lung cancer can enhance the cellular immune function and improve the quality of life in cancer patients, which is of great significance to improve the curative effect and prognosis.